StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.95−0.05 (-1.67%)

Close on Nov 17, 2026Market cap $268.41MP/E –Yield –

SAB Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

SAB Biotherapeutics's pe ratio was 13.4× on Apr 30, 2026, against 23.6× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202613.4×+3.9
2025Dec 31, 20259.5×−4.4
2022Jan 31, 202213.9×−4.8
2021Dec 31, 202118.6×–

More SAB Biotherapeutics figures

See a number that looks wrong?